{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:12:29Z","timestamp":1766268749288},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p>Patients with<jats:italic toggle=\"yes\">PDGFRA<\/jats:italic>-rearranged hematopoietic neoplasms typically present with chronic eosinophilic leukemia and rarely with acute myeloid leukemia or T-lymphoblastic lymphoma. However, mature T-cell lymphoma has not been previously associated with PDGFRA aberrations. We report a patient who presented with simultaneous T-lymphoblastic lymphoma, focal myeloid proliferation, and cutaneous cytotoxic T-cell lymphoma refractory to chemotherapy. The presence of myeloid and lymphoid lineages prompted genetic and molecular studies. A<jats:italic toggle=\"yes\">PDGFRA<\/jats:italic>rearrangement was identified in all compartments: cutaneous, lymph node, and bone marrow. Treatment with imatinib resulted in an excellent response in cutaneous and systemic disease. We report the first case of a mature cutaneous T-cell lymphoma with<jats:italic toggle=\"yes\">PDGFRA<\/jats:italic>rearrangement, expanding the spectrum of neoplasms associated with this genetic abnormality. Our case underscores the great importance of recognizing<jats:italic toggle=\"yes\">PDGFRA<\/jats:italic>rearrangement in unusual cases of cutaneous T-cell lymphoma, systemic lymphoid, and myeloid neoplasms. These patients may respond well to tyrosine kinase inhibitors, despite resistance to conventional chemotherapy.<\/jats:p>","DOI":"10.1097\/dad.0000000000001121","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T13:41:57Z","timestamp":1519998117000},"page":"610-613","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm"],"prefix":"10.1097","volume":"40","author":[{"given":"Amir","family":"Behdad","sequence":"first","affiliation":[{"name":"Department of Pathology, Northwestern University, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Northwestern University, Chicago, IL; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolong Alan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northwestern University, Chicago, IL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northwestern University, Chicago, IL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Northwestern University, Chicago, IL; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia."},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0609.2007.00973.x","article-title":"Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy","volume":"80","author":"Capovilla","year":"2008","journal-title":"Eur J Haematol."},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/ijlh.12596","article-title":"Synchronous T lymphoblastic lymphoma and myeloid neoplasm with PDGFRA rearrangement","volume":"39","author":"Pourabdollah","year":"2017","journal-title":"Int J Lab Hematol."},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2010.272","article-title":"PDGFRA rearrangement leading to hyper-eosinophilia, T-lymphoblastic lymphoma, myeloproliferative neoplasm and precursor B-cell acute lymphoblastic leukemia","volume":"25","author":"Huang","year":"2011","journal-title":"Leukemia."},{"key":"R7-20230908","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/PAP.0b013e31828d17ec","article-title":"Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma","volume":"20","author":"Ohgami","year":"2013","journal-title":"Adv Anat Pathol."},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med."},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000372-201808000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T18:24:48Z","timestamp":1719858288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201808000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001121","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}